Sources of Funding
Myocardial Infarction, Thrombolysis
HEART, MYOCARDIAL INFARCTION
This work was supported by grants from Merck & Co., Inc. to the University of Oxford. Support was also provided by the British Heart Foundation (including direct support for Professor Hopewell through grant FS/14/55/30806), the UK Medical Research Council (which funds the Medical Research Council Population Health Research Unit in a strategic partnership with the University of Oxford), the UK National Institute for Health Research Clinical Research Network, Health Data Research UK, the National Institute for Health Research Oxford Biomedical Research Centre, and the National Institute for Health Research Barts Biomedical Research Centre (NIHR203330). The REVEAL trial was designed, conducted, analyzed, and interpreted by independent investigators in the Clinical Trial Service Unit at the University of Oxford (the regulatory trial sponsor), Oxford, UK in collaboration with the Thrombolysis in Myocardial Infarction Study Group at Brigham and Women's Hospital and Harvard Medical School in Boston, MA, along with other members of the Steering Committee and Merck & Co, Inc., NJ. Merck funded the trial and provided trial drugs. The coauthors prepared the article, which was reviewed and approved by the trial Steering Committee. The decision to submit it for publication was independent of all funding sources. For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.